MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 16.03.2026
Assertio Holdings Operativer Cashflow 2011-2026 | ASRT
Operativer Cashflow Jährlich Assertio Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.2 M | 26.4 M | 49.6 M | 78.6 M | 5.52 M | -65.6 M | 90.5 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 90.5 M | -65.6 M | 22.4 M |
Operativer Cashflow Vierteljährlich Assertio Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -12.5 M | - | - | - | 7.51 M | - | - | - | 22.7 M | - | 51.9 M | 41.9 M | 27.4 M | - | 1.39 M | -3.26 M | -4.23 M | - | -59.6 M | -45.2 M | -25.1 M | - | 82.6 M | 48.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 82.6 M | -59.6 M | 9.59 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.43 | 3.31 % | $ 86.3 M |  Canada |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Pacira BioSciences
PCRX
|
189 M | $ 23.16 | -0.19 % | $ 1.07 B | USA |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 8.36 | 4.3 % | $ 428 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Perrigo Company plc
PRGO
|
238 M | $ 9.84 | 2.07 % | $ 1.36 B | USA |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.03 | -3.19 % | $ 42.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 1.08 | 4.37 % | $ 25.2 M | USA |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.2 | 4.0 % | $ 1.9 B | Canada |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
-156 M | $ 7.1 | 6.26 % | $ 621 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.4 | 1.82 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.34 | - | $ 2.9 M | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
-42.3 M | $ 4.44 | 0.23 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Tilray
TLRY
|
7.91 M | $ 7.02 | 5.45 % | $ 4.34 B | Canada |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 6.43 | 5.41 % | $ 254 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.39 | 3.84 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 0.92 | 2.51 % | $ 45.9 M | USA |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 0.59 | 3.79 % | $ 10.3 M |  China |
 |
Veru
VERU
|
-21.7 M | $ 2.3 | 0.44 % | $ 310 M | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Harrow Health
HROW
|
43.9 M | $ 36.09 | 2.53 % | $ 1.33 B | USA |
 |
Viatris
VTRS
|
2.9 B | $ 13.59 | 1.72 % | $ 16.3 B | USA |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.49 | 3.31 % | $ 328 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.0 | 4.19 % | $ 108 M | Canada |
 |
cbdMD
YCBD
|
-353 K | $ 0.79 | 2.82 % | $ 3.41 M | USA |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.28 | -0.44 % | $ 23.8 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |